Extended Data Fig. 4: Genes and pathways modulated by HER3-DXd.
From: Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
(a, b) Gene set enrichment analysis (GSEA), using the Hallmark gene set in the overall population (a) and in responders (b) showed upregulation of genes involved in immune response, particularly interferon alpha and gamma and complement signaling; (c) GSEA, using the Hallmark gene sets: Key activated/suppressed pathways in on treatment/baseline matched biopsies by comparing responders (n = 14 pairs) vs. non responders (n = 8 pairs), showing on-treatment activation of immune pathways in responders as compared non responders; (d) GSEA, using the Hallmark gene sets: Key activated/suppressed pathways in HER3-DXd-positive (HER3-DXd-positive cells ≥ 5%, n = 5) and HER3-DXd-negative tumors (HER3-DXd-positive cells < 5%, n = 7) on-treatment.
